Call Us: (800) 977-6110

  • Modafinil with CBT may improve drug rehab for gay men with HIV

    Posted on July 23, 2013
    Methamphetamine use has been linked to increased risk of human immunodeficiency virus (HIV) among gay men. Methamphetamine is a highly addictive stimulant that may lower inhibitions, increase sexual arousal, and lead to risky sexual behavior such as unprotected sex. Further, methamphetamine may be injected, and needle-sharing is also a risk factor for HIV.  These two epidemics have spread concurrently among gay men. There is a need for specialized approaches for addiction treatment and drug rehab for gay men with HIV, if such approaches could be developed. Researchers from the New York State Psychiatric Institute and Columbia University evaluated the efficacy of modafinil plus cognitive behavioral therapy as a treatment for methamphetamine dependence among gay men with HIV (McElhiney...
    full story
  • Aripiprazole (Abilify) in Alcohol Treatment & Recovery

    Posted on July 23, 2013
    Aripiprazole (Abilify) has been approved by the FDA for the treatment of schizophrenia and acute manic and mixed episodes of bipolar disorder and as an adjunct for the treatment of major depressive disorder. Although other FDA-approved atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, and ziprasidone) antagonize the D2 dopamine receptor, aripiprazole acts as a dopamine receptor partial agonist. Might a dopamine receptor partial agonist have a useful role in alcohol recovery? Antagonist vs. Agonist An agonist binds to a specific receptor and triggers a response that often mimics the response of another drug or naturally occurring substance. For example, methadone is an opioid agonist that mimics the effects of opiates. Antagonists, on the other hand, bind to ...
    full story